healthcare
China New Oriental CEO launches $32m angel fund
Michael Yu, co-founder and CEO of New Oriental Education & Technology Group, has partnered with Xitai Shen, a former CEO of Huatai United Securities, to launch a RMB200 million ($32 million) angel investment fund.
AIA, Nest set up accelerator for Hong Kong start-ups
AIA Group has teamed up with early-stage investor Nest to form a Hong Kong-based accelerator that will support start-ups with technologies relevant to the insurance and healthcare industries.
JD Capital buys traditional Chinese medicine business
JD Capital has bought a 60% stake in Baoding Zhong Yao, a traditional Chinese medicine (TCM) manufacturer.
BVCF leads Series A for Shanghai immunotherapy firm
China-focused healthcare investor BVCF has led an undisclosed Series A round of funding for CARsgen, an immunotherapy firm that focuses on treating cancer.
China's Ally Bridge ventures into German healthcare
Ally Bridge Group, a healthcare-focused PE firm based in Hong Kong and the US, has made its first investment in Europe, participating in a EUR6.6 million ($8 million) round of funding for Pieris, a Munich-based clinical-stage biotechnology firm.
Lighthouse leads $5m Series C round for hearing aid maker
Shanghai-based Lighthouse Capital has led a $5 million Series C round of funding for affordable hearing aid maker iHear Medical.
Fosun, Nanjing Sinolife to acquire New Zealand nutrients maker
Fosun Capital and Nanjing Sinolife United have formed a joint venture to acquire Good Health Products, a New Zealand-based nutritional supplements maker and distributor, for NZ$23.37 million ($18 million).
Fidelity commits $10m to China medical device maker Eyebright
Fidelity Growth Partners Asia and Fidelity Biosciences have committed RMB62.5 million ($10 million) to Eyebright Medical Technology, a Chinese ophthalmic medical devices manufacturer.
J-Star in hospice care double deal
Not for the first time, J-Star planted the seeds of its latest investment while in pursuit of another deal.
Taiwan's Fubon commits $30m to US-based Athyrium credit fund
Fubon Life, the second-largest insurer in Taiwan, has committed $30 million to Athyrium Capital Management’s healthcare-focused credit fund.
Baring Asia buys Japanese drug maker from Tokio Marine
Baring Private Equity Asia has agreed to buy Japan-based Bushu Pharmaceuticals from Tokio Marine Capital at an enterprise valuation of JPY77.3 billion ($670 million).
Hillhouse, CITIC PE commit $75m to Chinese cancer drug developer
Hillhouse Capital and CITIC Private Equity have participated in a RMB450 million ($75 million) round of funding for BeiGene, a Chinese company that develops drugs to combat cancer.
Japan's J-Star buys two healthcare providers
Japanese mid-market buyout firm J-Star has acquired two new care providers - Nagoya-headquartered Nurse Call and Kanagawa-based Kairos & Company - within weeks of its 5x exit from similar business HCM Corporation.
SIG, SoftBank back China wearables maker Codoon
SoftBank China Venture Capital (SBCVC) and SIG Asia have invested $30 million in a Series B round of funding for Codoon, a Chinese wearable electronic devices manufacturer.
Chinese pharma company invests $22m in TPG biotech fund
Chinese drug maker Shenzhen Hepalink Pharmaceutical, previously a highly successful PE investment for Goldman Sachs, has committed $22 million to TPG Capital’s latest biotech fund.
J-Star secures 5x exit from healthcare firm HCM - update
Japanese mid-market buyout firm J-Star has exited Tokyo-based healthcare service provider HCM Corporation to Alshok Group at an enterprise value of JPY8.88 billion ($78.7 million), generating a 5x cash multiple and a 60% IRR.
Hony eyes buyout opportunities in healthcare, restaurants
China-focused GP Hony Capital is seeing more buyout opportunities involving healthcare and restaurant chains and it has created two sector-focused operational teams to consolidate these industries.
Warburg Pincus invests $90m in India's Laurus Labs, Fidelity part exits
Warburg Pincus has paid INR5.5 billion ($89.6 million) for a minority stake in Indian drug maker Laurus Labs, triggering a partial exit for Fidelity Growth Partners India.
BVCF-backed Jaguar Animal Health targets $54m US IPO
Jaguar Animal Health, a veterinary drugs developer backed by China-focused healthcare investor BVCF, is looking to raise as much as $54 million through a NASDAQ IPO.
PE-backed Luye Pharma to take full ownership of Beijing Jialin
Luye Pharma Group, a PE-backed Chinese drug maker, has taken full ownership of its industry peer Beijing Jialin Pharmaceutical, acquiring a 42.02% interest from existing PE shareholders.
Fidelity Asia invests $15m in Chinese orthopedic hospital operator
Fidelity Growth Partners Asia has invested RMB90 million ($15 million) in Zhejiang Banger Medical Management, a Chinese orthopedic hospital operator.
Fidelity, Somerset back India's Cygnus Medicare
Fidelity Growth Partners and existing backer Somerset Indus CapitalFund have invested INR600 million ($9.7 million) in Cygnus Medicare, an Indian operator of specialty hospitals in Delhi and Haryana.
Qiming-backed life science firm BBI files for Hong Kong IPO
BBI Life Sciences Corporation, a Chinese genetic engineering specialist backed by Qiming Venture Partners, has filed for an IPO in Hong Kong. The company has yet to disclose the size and pricing of the offering.
US medical device maker gets $51m for China expansion
MID Labs, a US-based medical devices manufacturer that focuses on eye surgery, has received $51 million in funding from a group of investors to support its expansion into China.